Henry C Fung, Chair and Professor of Department of Bone Marrow Transplant and Cellular Therapy at Fox Chase Cancer Center, shared on X:
“AZA–VEN vs CLAD–LDAC–VEN: no winner yet.
CLAD provides elegant ara-CTP amplification. But comparing 21 days of VEN with CLAD against only 14 days with AZA is not a clean comparison of backbones.
OPTI-AML warns us: 14-day VEN failed noninferiority to 28 days, with the greatest loss of CR in NPM1/IDH2 AML.
Shortening VEN may disproportionately reduce remission in the AML genotypes most sensitive to VEN.
Match VEN exposure, genetics, fitness and transplantation before crowning a winner.”
You can also read: Acute Myeloid Leukemia (AML) in 2026: Current Practice and Evolving Directions
